Dynamic Precision Library (DPL) — computational biology-driven antibody discovery platform powering NEObody, SAFEbody, and POWERbody technologies for novel cancer immunotherapy development

NEObody

NEObody technology — antibody engineering platform targeting unique, evolutionarily conserved epitopes with species cross-reactivity; focus on oncology/immuno-oncology targets including CTLA-4 and CD137

SAFEbody · Sanofi

SAFEbody precision masking technology — proprietary platform that masks antibody binding sites for conditional activation in the tumor microenvironment, reducing on-target off-tumor toxicity; licensed to Sanofi and Exelixis for tumor targets

POWERbody

POWERbody technology — Fc-engineering and bispecific T-cell engager platform combining SAFEbody masking with enhanced effector function (IgG1 isotype and enhanced versions) for oncology; includes masked TCEs with co-stimulatory signals such as CD28

Discontinued (1)

ADG106 — undisclosed · deprioritized

Biotech Distilled coverage (6)

2026-05-08 UPDATE: Adagene (ADAG) – The Coil Tightens 🔒 Paid
2026-03-21 UPDATE: Adagene (ADAG) – The Whales Keep Circling 🔒 Paid
2026-02-21 UPDATE: Adagene (ADAG) – The Whale That Sold to the Whale 🔒 Paid
2026-01-30 UPDATE: Adagene (ADAG) – Following the Smart Money 🔒 Paid
2026-01-25 UPDATE: Adagene (ADAG) – Did The Dilution Gap Just Close? 🔒 Paid
2026-01-02 Adagene Inc (ADAG): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.